Genmab AS (NASDAQ:GMAB) — Market Cap & Net Worth
Market Cap & Net Worth: Genmab AS (GMAB)
Genmab AS (NASDAQ:GMAB) has a market capitalization of $15.19 Billion ($15.19 Billion) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #1627 globally and #623 in its home market, demonstrating a -0.24% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Genmab AS's stock price $24.74 by its total outstanding shares 613910580 (613.91 Million). Review how much debt does Genmab AS carry to assess the company's total debt and financial obligations.
Genmab AS Market Cap History: 2015 to 2026
Genmab AS's market capitalization history from 2015 to 2026. Data shows growth from $8.23 Billion to $15.19 Billion (9.60% CAGR).
Index Memberships
Genmab AS is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$919.19 Billion | 1.65% | #16 of 30 |
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.62% | #26 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.04% | #189 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.89% | #18 of 263 |
Weight: Genmab AS's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Genmab AS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Genmab AS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.08x
Genmab AS's market cap is 5.08 times its annual revenue
Latest Price to Earnings (P/E) Ratio
19.62x
Genmab AS's market cap is 19.62 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $10.18 Billion | $1.82 Billion | $1.19 Billion | 5.61x | 8.58x |
| 2017 | $10.18 Billion | $2.37 Billion | $1.10 Billion | 4.30x | 9.22x |
| 2018 | $10.11 Billion | $3.03 Billion | $1.47 Billion | 3.34x | 6.87x |
| 2019 | $13.71 Billion | $5.37 Billion | $2.17 Billion | 2.55x | 6.33x |
| 2020 | $24.96 Billion | $10.11 Billion | $4.76 Billion | 2.47x | 5.25x |
| 2021 | $24.29 Billion | $8.42 Billion | $2.96 Billion | 2.89x | 8.21x |
| 2022 | $26.02 Billion | $14.51 Billion | $5.45 Billion | 1.79x | 4.77x |
| 2023 | $19.55 Billion | $16.47 Billion | $4.35 Billion | 1.19x | 4.49x |
| 2024 | $12.81 Billion | $21.53 Billion | $7.84 Billion | 0.60x | 1.63x |
| 2025 | $18.91 Billion | $3.72 Billion | $963.76 Million | 5.08x | 19.62x |
Competitor Companies of GMAB by Market Capitalization
Companies near Genmab AS in the global market cap rankings as of June 17, 2026.
Key companies related to Genmab AS by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Genmab AS Historical Marketcap From 2015 to 2026
Between 2015 and today, Genmab AS's market cap moved from $8.23 Billion to $ 15.19 Billion, with a yearly change of 9.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $15.19 Billion | -19.68% |
| 2025 | $18.91 Billion | +47.58% |
| 2024 | $12.81 Billion | -34.45% |
| 2023 | $19.55 Billion | -24.87% |
| 2022 | $26.02 Billion | +7.13% |
| 2021 | $24.29 Billion | -2.71% |
| 2020 | $24.96 Billion | +82.09% |
| 2019 | $13.71 Billion | +35.54% |
| 2018 | $10.11 Billion | -0.61% |
| 2017 | $10.18 Billion | -0.04% |
| 2016 | $10.18 Billion | +23.73% |
| 2015 | $8.23 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Genmab AS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.19 Billion USD |
| MoneyControl | $15.19 Billion USD |
| MarketWatch | $15.19 Billion USD |
| marketcap.company | $15.19 Billion USD |
| Reuters | $15.19 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Genmab AS
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervi… Read more